In vivo switching of human melanoma cells between proliferative and invasive states.

Metastatic melanoma represents a complex and heterogeneous disease for which there are no therapies to improve patient survival. Recent expression profiling of melanoma cell lines identified two transcription signatures, respectively, corresponding with proliferative and invasive cellular phenotypes. A model derived from these findings predicts that in vivo melanoma cells may switch between these states. Here, DNA microarray-characterized cell lines were subjected to in vitro characterization before s.c. injection into immunocompromised mice. Tumor growth rates were measured and postexcision samples were assessed by immunohistochemistry to identify invasive and proliferative signature cells. In vitro tests showed that proliferative signature melanoma cells are faster growing but less motile than invasive signature cells. In vivo proliferative signature cells initiated tumor growth in 14 +/- 3 days postinjection. By comparison, invasive signature cells required a significantly longer (P < 0.001) period of 59 +/- 11 days. Immunohistochemistry showed that regardless of the seed cell signature, tumors showed evidence for both proliferative and invasive cell types. Furthermore, proliferative signature cell types were detected most frequently in the peripheral margin of growing tumors. These data indicate that melanoma cells undergo transcriptional signature switching in vivo likely regulated by local microenvironmental conditions. Our findings challenge previous models of melanoma progression that evoke one-way changes in gene expression. We present a new model for melanoma progression that accounts for transcription signature plasticity and provides a more rational context for explaining observed melanoma biology.

[1]  Química Microphthalmia-Associated Transcription Factor , 2010 .

[2]  G. Salti,et al.  Role of microphthalmia transcription factor (Mitf) in melanoma differentiation. , 2007, Biochemical and biophysical research communications.

[3]  A. Sasse,et al.  Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. , 2007, The Cochrane database of systematic reviews.

[4]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[5]  D. Ribatti,et al.  Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination , 2006, Clinical and Experimental Medicine.

[6]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[7]  M. Hendrix,et al.  Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.

[8]  M. Hendrix,et al.  Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Meltzer,et al.  The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment , 2006, Journal of cellular and molecular medicine.

[10]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[11]  A. Jacobs,et al.  Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[13]  S. Byers,et al.  The role of TGF-β and Wnt signaling in gastrointestinal stem cells and cancer , 2005, Oncogene.

[14]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[15]  M. Khaled,et al.  Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells , 2005, The Journal of cell biology.

[16]  B. Ljung,et al.  The gene expression signatures of melanoma progression , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Larue,et al.  Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.

[18]  R. Delston,et al.  MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A , 2005, The Journal of cell biology.

[19]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[20]  N. Copeland,et al.  Melanocytes and the microphthalmia transcription factor network. , 2004, Annual review of genetics.

[21]  R. Krumlauf,et al.  Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex , 2004, Development.

[22]  Naoto Ueno,et al.  The TAK1-NLK Mitogen-Activated Protein Kinase Cascade Functions in the Wnt-5a/Ca2+ Pathway To Antagonize Wnt/β-Catenin Signaling , 2003, Molecular and Cellular Biology.

[23]  M. Okabe,et al.  Small interfering RNA and gene silencing in transgenic mice and rats , 2002, FEBS letters.

[24]  Stephen L. Lessnick,et al.  β-Catenin–induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor , 2002, The Journal of Cell Biology.

[25]  D. Fisher,et al.  Identification of Aim-1 as the underwhiteMouse Mutant and Its Transcriptional Regulation by MITF* , 2002, The Journal of Biological Chemistry.

[26]  A. Zorn,et al.  Wnt signalling: Antagonistic Dickkopfs , 2001, Current Biology.

[27]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[28]  Harris,et al.  Morphological and immunophenotypic variations in malignant melanoma , 2000, Histopathology.

[29]  R. Dummer,et al.  The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. , 1998, Human gene therapy.

[30]  R. Dummer,et al.  Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. , 1998, The Journal of investigative dermatology.

[31]  A. Bassols,et al.  The effect of TGF-beta 1 on cell proliferation and proteoglycan production in human melanoma cells depends on the degree of cell differentiation. , 1996, Cancer letters.

[32]  C. Garbe,et al.  Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. , 1994, Anticancer research.

[33]  J. Gerdes,et al.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins , 1993, The Journal of cell biology.

[34]  S. Bruno,et al.  Cell cycle dependent expression and stability of the nuclear protein detected by Ki‐67 antibody in HL‐60 cells , 1992, Cell proliferation.

[35]  A. Levene On the histological diagnosis and prognosis of malignant melanoma. , 1980, Journal of clinical pathology.

[36]  A. Breslow Tumor thickness in evaluating prognosis of cutaneous melanoma. , 1978, Annals of surgery.

[37]  H. Dardik Umbilical vein grafts. , 1978, Annals of surgery.

[38]  I. Fidler,et al.  Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.

[39]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[40]  S. Påhlman,et al.  Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. , 2006, Advances in experimental medicine and biology.

[41]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[42]  R. Buscà,et al.  [Hypoxia inducible factor 1a is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells]. , 2006, Medecine sciences : M/S.

[43]  S. Byers,et al.  The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. , 2005, Oncogene.

[44]  H. Müller-Hermelink,et al.  Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.

[45]  M. Sporn,et al.  Type beta transforming growth factor: a bifunctional regulator of cellular growth. , 1985, Proceedings of the National Academy of Sciences of the United States of America.